Drug intelligence / Profile preview

MK-0873 Patch

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Topical, Transdermal

Overview

MK-0873 Patch is a topical formulation of MK-0873, a selective phosphodiesterase 4 (PDE4) inhibitor. It was developed by Merck Sharp & Dohme Corp. for the treatment of psoriasis. The mechanism of action involves inhibition of PDE4, which increases intracellular cAMP levels and reduces inflammation by decreasing the production of pro-inflammatory cytokines such as TNF-alpha.

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on MK-0873 Patch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0873 Patch.

Explore the full profile